Copyright investors
On Monday, Agios Pharmaceuticals (AGIO) hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 78 the day before. This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market. Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they launch their biggest price moves. Agios Pharmaceuticals is trading within a buy range after climbing above a 41.74 entry in a consolidation. The proper buying range is up to 5% above the initial entry. Once a stock moves above that range, it's best to hold off investing and wait for it to set up another buying opportunity. Agios Pharmaceuticals reported 0% EPS growth in the latest quarterly report, while sales growth came in at 44%. Agios Pharmaceuticals earns the No. 190 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Krystal Biotech (KRYS) and Travere Therapeutics (TVTX) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
